Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions: <i>JACC: CardioOncology</i> State-of-the-Art Review.

Tan, Sean; Day, Daphne; Nicholls, Stephen J; Segelov, Eva

Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions: JACC: CardioOncology State-of-the-Art Review.

Tan, Sean; Day, Daphne; Nicholls, Stephen J; Segelov, Eva.

Afiliación

Tan S; Victorian Heart Institute, Monash University, Melbourne, Victoria, Australia.
Day D; Monash Heart, Monash Health, Clayton, Victoria, Australia.
Nicholls SJ; School of Clinical Sciences, Monash Health, Monash University, Melbourne, Victoria, Australia.
Segelov E; Department of Oncology, Monash Health, Clayton, Victoria, Australia.

JACC CardioOncol ; 4(5): 579-597, 2022 Dec.

Article en En | MEDLINE | ID: mdl-36636451

Palabras clave

CTLA-4, cytotoxic T lymphocyte associated antigen 4; ICI, immune checkpoint inhibitors; LAG-3, lymphocyte-activation gene 3; MSI, microsatellite instability; PD-L1, programmed death-ligand 1; TMB, tumor mutational burden; TME, tumor microenvironment; biomarkers; cardio-oncology; cardiotoxicity; immune checkpoint inhibitors; immune related adverse events; immunotherapy; irAE, immune-related adverse event; medical oncology

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: JACC CardioOncol Año: 2022 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google